Selected research
Industry Research
Soft Capsules Drugs Industry Research Report 2026
Market perspective
The global Soft Capsules Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Soft Capsules Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Soft Capsules Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Soft Capsules Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Soft Capsules Drugs include GSK, A&Z Pharmaceutical, Atrium Innovations, Blackmores, Boehringer Ingelheim, By-health, Chiesi, Nature Made and Sumitomo Dainippon, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Soft Capsules Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Soft Capsules Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Soft Capsules Drugs Market by Company
GSK
A&Z Pharmaceutical
Atrium Innovations
Blackmores
Boehringer Ingelheim
By-health
Chiesi
Nature Made
Sumitomo Dainippon
The Clorox Company
Vertex
AstraZeneca
Roche
Merck
Novartis
Teva
Abbott
Soft Capsules Drugs Segment by Type
Liquid Core Drugs
Semi-solid Core Drugs
Soft Capsules Drugs Segment by Application
Hospital Pharmacy
Retail Pharmacy
Soft Capsules Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soft Capsules Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Soft Capsules Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soft Capsules Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Soft Capsules Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid Core Drugs
- Semi-solid Core Drugs
Applications
- Hospital Pharmacy
- Retail Pharmacy
Companies covered
- GSK
- A&Z Pharmaceutical
- Atrium Innovations
- Blackmores
- Boehringer Ingelheim
- By-health
- Chiesi
- Nature Made
- Sumitomo Dainippon
- The Clorox Company
- Vertex
- AstraZeneca
- Roche
- Merck
- Novartis
- Teva
- Abbott
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Soft Capsules Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liquid Core Drugs
- 2.2.3 Semi-solid Core Drugs
- 2.3 Soft Capsules Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Retail Pharmacy
- 2.4 Assumptions and Limitations
3 Soft Capsules Drugs Breakdown Data by Type
- 3.1 Global Soft Capsules Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Soft Capsules Drugs Forecasted Market Size by Type (2027-2032)
4 Soft Capsules Drugs Breakdown Data by Application
- 4.1 Global Soft Capsules Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Soft Capsules Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Soft Capsules Drugs Market Perspective (2021-2032)
- 5.2 Global Soft Capsules Drugs Growth Trends by Region
- 5.2.1 Global Soft Capsules Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Soft Capsules Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Soft Capsules Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Soft Capsules Drugs Market Dynamics
- 5.3.1 Soft Capsules Drugs Industry Trends
- 5.3.2 Soft Capsules Drugs Market Drivers
- 5.3.3 Soft Capsules Drugs Market Challenges
- 5.3.4 Soft Capsules Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Soft Capsules Drugs Players by Revenue
- 6.1.1 Global Top Soft Capsules Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Soft Capsules Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Soft Capsules Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Soft Capsules Drugs Head Office and Area Served
- 6.4 Global Soft Capsules Drugs Players, Product Type & Application
- 6.5 Global Soft Capsules Drugs Manufacturers Established Date
- 6.6 Global Soft Capsules Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Soft Capsules Drugs Market Size (2021-2032)
- 7.2 North America Soft Capsules Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Soft Capsules Drugs Market Size by Country (2021-2026)
- 7.4 North America Soft Capsules Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Soft Capsules Drugs Market Size (2021-2032)
- 8.2 Europe Soft Capsules Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Soft Capsules Drugs Market Size by Country (2021-2026)
- 8.4 Europe Soft Capsules Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Soft Capsules Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Soft Capsules Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Soft Capsules Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Soft Capsules Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Soft Capsules Drugs Market Size (2021-2032)
- 10.2 South America Soft Capsules Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Soft Capsules Drugs Market Size by Country (2021-2026)
- 10.4 South America Soft Capsules Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Soft Capsules Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Soft Capsules Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Soft Capsules Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Soft Capsules Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.1.4 GSK Soft Capsules Drugs Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 A&Z Pharmaceutical
- 12.2.1 A&Z Pharmaceutical Company Information
- 12.2.2 A&Z Pharmaceutical Business Overview
- 12.2.3 A&Z Pharmaceutical Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.2.4 A&Z Pharmaceutical Soft Capsules Drugs Product Portfolio
- 12.2.5 A&Z Pharmaceutical Recent Developments
- 12.3 Atrium Innovations
- 12.3.1 Atrium Innovations Company Information
- 12.3.2 Atrium Innovations Business Overview
- 12.3.3 Atrium Innovations Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.3.4 Atrium Innovations Soft Capsules Drugs Product Portfolio
- 12.3.5 Atrium Innovations Recent Developments
- 12.4 Blackmores
- 12.4.1 Blackmores Company Information
- 12.4.2 Blackmores Business Overview
- 12.4.3 Blackmores Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.4.4 Blackmores Soft Capsules Drugs Product Portfolio
- 12.4.5 Blackmores Recent Developments
- 12.5 Boehringer Ingelheim
- 12.5.1 Boehringer Ingelheim Company Information
- 12.5.2 Boehringer Ingelheim Business Overview
- 12.5.3 Boehringer Ingelheim Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.5.4 Boehringer Ingelheim Soft Capsules Drugs Product Portfolio
- 12.5.5 Boehringer Ingelheim Recent Developments
- 12.6 By-health
- 12.6.1 By-health Company Information
- 12.6.2 By-health Business Overview
- 12.6.3 By-health Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.6.4 By-health Soft Capsules Drugs Product Portfolio
- 12.6.5 By-health Recent Developments
- 12.7 Chiesi
- 12.7.1 Chiesi Company Information
- 12.7.2 Chiesi Business Overview
- 12.7.3 Chiesi Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.7.4 Chiesi Soft Capsules Drugs Product Portfolio
- 12.7.5 Chiesi Recent Developments
- 12.8 Nature Made
- 12.8.1 Nature Made Company Information
- 12.8.2 Nature Made Business Overview
- 12.8.3 Nature Made Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.8.4 Nature Made Soft Capsules Drugs Product Portfolio
- 12.8.5 Nature Made Recent Developments
- 12.9 Sumitomo Dainippon
- 12.9.1 Sumitomo Dainippon Company Information
- 12.9.2 Sumitomo Dainippon Business Overview
- 12.9.3 Sumitomo Dainippon Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.9.4 Sumitomo Dainippon Soft Capsules Drugs Product Portfolio
- 12.9.5 Sumitomo Dainippon Recent Developments
- 12.10 The Clorox Company
- 12.10.1 The Clorox Company Company Information
- 12.10.2 The Clorox Company Business Overview
- 12.10.3 The Clorox Company Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.10.4 The Clorox Company Soft Capsules Drugs Product Portfolio
- 12.10.5 The Clorox Company Recent Developments
- 12.11 Vertex
- 12.11.1 Vertex Company Information
- 12.11.2 Vertex Business Overview
- 12.11.3 Vertex Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.11.4 Vertex Soft Capsules Drugs Product Portfolio
- 12.11.5 Vertex Recent Developments
- 12.12 AstraZeneca
- 12.12.1 AstraZeneca Company Information
- 12.12.2 AstraZeneca Business Overview
- 12.12.3 AstraZeneca Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.12.4 AstraZeneca Soft Capsules Drugs Product Portfolio
- 12.12.5 AstraZeneca Recent Developments
- 12.13 Roche
- 12.13.1 Roche Company Information
- 12.13.2 Roche Business Overview
- 12.13.3 Roche Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.13.4 Roche Soft Capsules Drugs Product Portfolio
- 12.13.5 Roche Recent Developments
- 12.14 Merck
- 12.14.1 Merck Company Information
- 12.14.2 Merck Business Overview
- 12.14.3 Merck Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.14.4 Merck Soft Capsules Drugs Product Portfolio
- 12.14.5 Merck Recent Developments
- 12.15 Novartis
- 12.15.1 Novartis Company Information
- 12.15.2 Novartis Business Overview
- 12.15.3 Novartis Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.15.4 Novartis Soft Capsules Drugs Product Portfolio
- 12.15.5 Novartis Recent Developments
- 12.16 Teva
- 12.16.1 Teva Company Information
- 12.16.2 Teva Business Overview
- 12.16.3 Teva Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.16.4 Teva Soft Capsules Drugs Product Portfolio
- 12.16.5 Teva Recent Developments
- 12.17 Abbott
- 12.17.1 Abbott Company Information
- 12.17.2 Abbott Business Overview
- 12.17.3 Abbott Revenue in Soft Capsules Drugs Business (2021-2026)
- 12.17.4 Abbott Soft Capsules Drugs Product Portfolio
- 12.17.5 Abbott Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst